Low virological response to interferon in children with chronic hepatitis C

Journal of Hepatology

Volumn 31, Issue 4, 1999, Pages 604-611

  Pensati, Pasqualina ^a   Iorio, Raffaele ^b   Botta, Salvatore ^b   Tuccillo, Concetta ^b   Donetto, Sara ^b   Vajro, Pietro ^b   Ciarlo, Giuseppina ^b   Vegnente, Angela ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NONE

Author keywords

Children; Chronic hepatitis; HCV viral load; Hepatitis C virus; Interferon alfa; Viral clearance

Indexed keywords

ALPHA2B INTERFERON; INTERFERON;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; CHILD; CHRONIC HEPATITIS; CLINICAL ARTICLE; EPISTAXIS; FEBRILE CONVULSION; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER FUNCTION TEST; MALE; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD;

EID: 0032863260     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80338-9     Document Type: Article

References (48)

1. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med. 336:1997;347-356.
2. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon-alpha: a multicenter randomized controlled trial. N Engl J Med. 321:1989;1501-1506.
3. Di Bisceglie AM. Interferon therapy for chronic viral hepatitis. [editorial] N Engl J Med. 330:1994;137-138.
4. Fried MW, Hoofnagle JH. Therapy of hepatitis C. Semin Liver Dis. 15:1995;82-91.
5. Carithers RL, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon-alpha2b trials. Hepatology. 26:1997;83S-88S.
6. Farrell GC. Therapy of hepatitis C: interferon-alphaN1 trials. Hepatology. 26:1997;96S-100S.
7. Lindsay KL. Therapy of hepatitis C: overview. Hepatology. 26:1997;71S-77S.
8. Keeffe EB, Hollinger FB. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon study group. Hepatology. 26:1997;101S-107S.
9. Lee WN. Therapy of hepatitis C: interferon alfa-2a trials. Hepatology. 26:1996;89S-95S.
10. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology. 15:1992;1013-1016.
11. Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, et al. Long-term follow up of patients with chronic hepatitis C treated with different doses of interferon-alpha2b. Hepatology. 18:1993;1300-1305.
12. Castillo I, Bartolomè J, Navas S, Gonzales S, Herrero M, Carreno V. Virological and biochemical long-term follow up of patients with chronic hepatitis C treated with interferon. Hepatology. 19:1994;1342-1346.
13. Bortolotti F, Giacchino R, Vajro P, Barbera C, Crivellaro C, Alberti A, et al. Recombinant interferon-alpha therapy in children with chronic hepatitis C. Hepatology. 22:1995;1623-1626.
14. Fujisawa T, Inui A, Ohkawa T, Komatsu H, Miyakawa Y, Onoue M. Response to interferon therapy in children with chronic hepatitis C. J Pediatr. 127:1995;660-662.
15. Iorio R, Pensati P, Porzio S, Fariello I, Guida S, Vegnente A. Lymphoblastoid alpha-interferon therapy in chronic hepatitis C. Arch Dis Child. 74:1996;152-156.
16. Matsuoka S, Mori K, Nakano O, Yuasa Y, Taguchi Y, Hayabuchi Y, et al. Efficacy of interferon in treating children with chronic hepatitis C. Eur J Pediatr. 156:1997;704-708.
17. Jonas M, Ott MJ, Nelson SP, Badizadegan K, Perez-Atayde AR. Interferon-alpha treatment of chronic hepatitis C virus infection in children. Pediatr Infect Dis J. 17:1998;241-246.
18. Sawada A, Tajiri H, Kozaiwa K, Guo W, Tada K, Etani Y, et al. Favorable response to lymphoblastoid interferon-alpha in children with chronic hepatitis C. J Hepatol. 28:1998;184-188.
19. Collins ML, Zayati C, Detmer JJ, Daly B, Kolberg JA, Cha T-A, et al. Preparation and characterization of RNA standards for use in quantitative branched DNA hybridization assays. Anal Biochem. 226:1995;120-129.
20. Davis GL, Lau JYN, Urdea MS, Neuwald P, Wilber JC, Lindsay K, et al. Quantitative detection of hepatitis C virus RNA by a solid phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology. 19:1994;1337-1341.
21. Alter HJ, Sanchez-Pescador R, Urdea MS, Wilber JC, Lagier RJ, Di Bisceglie AM, et al. Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA. J Viral Hepatitis. 2:1995;121-132.
22. Nelson DR, Marousis CG, Davis GL, Lau JYN. Defining the role of intrahepatic HCV-specific cytotoxic T-lymphocytes in chronic hepatitis C. [abstract] Hepatology. 22:1995;287A.
23. Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology. 103:1992;317-322.
24. Davis GL. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol. 21:1994;1-3.
25. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology. 22:1995;1050-1056.
26. Conjeevaram HS, Everhart JE, Hoofnagle JH. Predictors of a sustained beneficial response to interferon alfa therapy in chronic hepatitis C. Hepatology. 22:1995;1326-1329.
27. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Safety. 10:1994;115-150.
28. Iorio R, Pensati P, Botta S, Moschella S, Impagliazzo N, Vajro P, et al. Side effects of alpha-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis. Pediatr Infect Dis J. 16:1997;984-990.
29. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology. 15:1992;567-571.
30. Desmet VJ, Gerber M. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 19:1994;1513-1520.
31. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology. 18:1993;998-1050.
32. Davis GL, Balart LA, Schiff ER, Linsay K, Bodenheimer HC, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicentre randomized controlled trial. N Engl J Med. 321:1989;1501-1506.
33. Davis GL. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol. 20:1994;1-3.
34. Vergani D, Mieli-Vergani G. Type II autoimmune hepatitis: the conundrum of cytochrome P450IID6. Clin Exp Immunol. 92:1993;367-368.
35. Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi PL, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med. 330:1994;751-756.
36. Lunel F, Musset L, Cacoub P, Frangeul L, Cresta P, Perrin M, et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology. 106:1994;1291-1300.
37. Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology. 102:1992;2155-2160.
38. Tran A, Quaranta JF, Benzaken S, Thiers V, Chau HT, Hastier P, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology. 18:1993;253-257.
39. Detmer J, Lagier R, Flynn J, Zayati C, Kolberg J, Collins M, et al. Accurate quantification of HCV-RNA from all HCV genotypes using branched DNA (b-DNA) technology. J Clin Microbiol. 34:1996;901-907.
40. Simmonds P, McOmish F, Yap PL, Chan SW, Lin CK, Dusheiko G, et al. Sequence variability in the 5′ non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. J Gen Virol. 74:1993;661-668.
41. Ma Y, Gregorio G, Gaken J, Muratori L, Bianchi FB, Mieli-Vergani G, et al. Establishment of a novel radioligand assay using eukaryotically expressed cytochrome P4502D6 for the measurement of liver kidney microsomal type 1 antibody in patients with autoimmune hepatitis and hepatitis C virus infection. J Hepatol. 26:1997;1396-1402.
42. Farrell GC, Bacon BR, Goldin RD. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study. Hepatology. 27:1998;1121-1127.
43. Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, et al. Slow progression rate of fibrosis in HCV patients with persistently normal ALT activity. Hepatology. 27:1998;868-872.
44. Baron S, Tyring SK, Fleischmann WR Jr, Coppenhaver DH, Niesel DW, Klimpel GR, et al. The interferons. Mechanisms of action and clinical applications. JAMA. 266:1991;1375-1383.
45. Oldstone MBA. Molecular mimicry and autoimmune disease. Cell. 50:1987;819-820.
46. Gregorio GV, Choudhuri K, Mieli-Vergani G, Vergani D. Mimicry between HBV-DNA polymerase and antigenic targets of nuclear and smooth-muscle antibodies in chronic hepatitis B virus infection. [abstract] Hepatology. 24:1996;28A.
47. Gregorio GV, Pensati P, Iorio R, Vegnente A, Mieli-Vergani G, Vergani D. Autoantibody prevalence in children with liver disease due to chronic hepatitis C virus (HCV) infection. Clin Exp Immunol. 112:1998;471-476.
48. McHutchison JG, Gordon SC, Schiff ER, Schiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 339:1998;1485-1492.